InvestorsHub Logo

couldbebetter

02/15/18 10:33 AM

#122654 RE: marzan #122650

I think that if BP were to buy out AMRN it would be done by one capable
of running a number of additional trials in order to capture more in-
dications. Tiva would not be one of those. Again, I am not advocating
a takeover of AMRN, I would like to see Vascepa eventually indicated for
much more than just CVD.